Explore

Search ClinicalTrials.gov

Find trials by condition, intervention, sponsor, or location. Filter by status, phase, and study type — or enter an NCT ID to jump straight to a trial.

Find trials by sponsor or company

Search by sponsors

RecruitingPhase IIIPhase III recruiting

StatusPhaseStudy typeSort

Results for “AstraZeneca”

A Phase 2 Study of Cediranib in Combination With Olaparib in Advanced Solid TumorsActive Not Recruiting
NCT02498613Phase 2Updated Jun 17, 2026
Sponsor: National Cancer Institute (NCI)
Advanced Malignant Solid Neoplasm · Metastatic Lung Non-Small Cell Carcinoma · Metastatic Lung Small Cell Carcinoma · Metastatic Pancreatic Adenocarcinoma
United States, Canada
Phase I Study of [111In]-FPI-2107 in EGFR Mutation-positive NSCLCRecruiting
NCT07500987Phase 1Updated Jun 17, 2026
Sponsor: AstraZeneca
EGFR Mutation-positive NSCLC
China
A Study of AZD0486 in Subjects With B-Cell Non-Hodgkin LymphomaActive Not Recruiting
NCT04594642Phase 1Updated Jun 17, 2026
Sponsor: AstraZeneca
B-cell Non Hodgkin Lymphoma · Diffuse Large B Cell Lymphoma · High-grade B-cell Lymphoma · Follicular Lymphoma
United States, Australia, Japan, South Korea, Taiwan
A Study to Investigate Efficacy and Safety of Ceralasertib Plus Durvalumab in Participants Aged ≥ 18 Years With Advanced or Metastatic Non-small Cell Lung Cancer Whose Disease Progressed on or After Prior Anti-PD-(L)1 Therapy and Platinum-based ChemotherapyActive Not Recruiting
NCT05941897Phase 2Updated Jun 17, 2026
Sponsor: AstraZeneca
Advanced or Metastatic NSCLC
Russia
SAPHNELO Systemic Lupus Erythematosus Japan Post-Marketing Surveillance (PMS)Active Not Recruiting
NCT05141201N/AUpdated Jun 17, 2026
Sponsor: AstraZeneca
Lupus Erythematosus, Systemic
Japan
A Phase I Study Comparing the Relative Bioavailability of a Fixed-Dose Combination of Laroprovstat/Rosuvastatin vs Their Single Therapy Products in Healthy AdultsCompleted
NCT07316608Phase 1Updated Jun 17, 2026
Sponsor: AstraZeneca
Healthy Participants
United States
Baxdrostat and Ventricular RemodelingNot Yet Recruiting
NCT07655362Phase 3Updated Jun 17, 2026
Sponsor: Subodh Verma
Cardiac Remodeling
Canada
A French Real-life Study: EvaluatioN of durvALumab Utilization and Effectiveness for First Line Extensive Stage Small Cell Lung Cancer.Active Not Recruiting
NCT05683977N/AUpdated Jun 16, 2026
Sponsor: AstraZeneca
Small Cell Lung Carcinoma
France
CHARM Hepatocellular Carcinoma MEA StudyNot Yet Recruiting
NCT07650773N/AUpdated Jun 16, 2026
Sponsor: AstraZeneca
HepatoCellular Carcinoma
A Phase Ⅲ Study of Rilvegostomig in Combination With Fluoropyrimidine and Trastuzumab Deruxtecan as the First-line Treatment for HER2-positive Gastric CancerRecruiting
NCT06764875Phase 3Updated Jun 16, 2026
Sponsor: AstraZeneca
HER2-positive Gastric Cancer · Gastroesophageal Junction Adenocarcinoma
United States, Argentina, Australia, Austria, Belgium +23 more
Anifrolumab Real-world Treatment Outcomes in Systemic Lupus ErythematosusActive Not Recruiting
NCT06673043N/AUpdated Jun 16, 2026
Sponsor: AstraZeneca
Lupus Erythematosus, Systemic
Poland
An Ophthalmic Safety Study in Patients With Breast CancerActive Not Recruiting
NCT06767462N/AUpdated Jun 16, 2026
Sponsor: AstraZeneca
Ophthalmic Safety in Patients With Breast Cancer
United States, Argentina, Belgium, Brazil, Canada +6 more
Dapagliflozin and Effect on Cardiovascular Events in Acute Heart Failure -Thrombolysis in Myocardial Infarction 68 (DAPA ACT HF-TIMI 68)Completed
NCT04363697Phase 4Updated Jun 16, 2026
Sponsor: The TIMI Study Group
Acute Heart Failure · Heart Failure
United States
Study of Acalabrutinib Versus Chlorambucil Plus Rituximab in Adult Subjects With Previously Untreated Chronic Lymphocytic LeukemiaActive Not Recruiting
NCT04075292Phase 3Updated Jun 16, 2026
Sponsor: AstraZeneca
Untreated Chronic Lymphocytic Leukemia
China, Philippines, Taiwan, Thailand, Vietnam
Treatment and Biomarker Testing Patterns,Treatment Outcomes in a/m NSCLC With and Without Actionable Genomic AlterationsActive Not Recruiting
NCT06245837N/AUpdated Jun 15, 2026
Sponsor: AstraZeneca
Non-small-cell Lung Cancer
Russia
Open-label Study to Assess Reduction of Background Asthma Medication While Sustaining Asthma Control and Clinical Remission With Tezepelumab in Patients 12-80yrs With Severe Asthma.Active Not Recruiting
NCT06473779Phase 3Updated Jun 15, 2026
Sponsor: AstraZeneca
Severe Asthma
United States, Argentina, Belgium, Bulgaria, Canada +7 more
A Study to Investigate the Safety and Pharmacokinetics of Single- and Multiple-ascending Doses of AZD4916 in Healthy VolunteersNot Yet Recruiting
NCT06951880Phase 1Updated Jun 15, 2026
Sponsor: AstraZeneca
Healthy Participants
United States, United Kingdom
TROP2 NMR Concordance StudyNot Yet Recruiting
NCT07624318N/AUpdated Jun 15, 2026
Sponsor: AstraZeneca
Lung Cancer
China
A Study of Dato-DXd With or Without Durvalumab Versus Investigator's Choice of Therapy in Patients With Stage I-III Triple-negative Breast Cancer Without Pathological Complete Response Following Neoadjuvant Therapy (TROPION-Breast03)Active Not Recruiting
NCT05629585Phase 3Updated Jun 15, 2026
Sponsor: AstraZeneca
Breast Cancer
United States, Belgium, Brazil, Canada, China +12 more
CT Air-trapping for the Early Identification of Benralizumab Responders Among Eosinophilic Asthma PatientsCompleted
NCT03976310NAUpdated Jun 15, 2026
Sponsor: University Hospital, Montpellier
Asthma
France
Does Cediranib Prevent Bowel Perforation in Platinum-resistant Ovarian CancerCompleted
NCT07648745Phase 2Updated Jun 15, 2026
Sponsor: Prof Gordon Jayson
Bowel Obstruction · Ovarian Cancer · Fallopian Tube Cancer · Primary Peritoneal Cancer
United Kingdom
EVOLVE Study: The Real-life Clinical Practice With Tezepelumab in GreeceActive Not Recruiting
NCT06724575N/AUpdated Jun 15, 2026
Sponsor: AstraZeneca
Asthma
Greece
A Study to Investigate Efficacy and Safety With Oral AZD9833 Compared With Intramuscular Fulvestrant in Post-menopausal Women at Least 18 Years of Age With Advanced ER-positive HER2 Negative Breast CancerActive Not Recruiting
NCT04214288Phase 2Updated Jun 15, 2026
Sponsor: AstraZeneca
Advanced ER-Positive HER2-Negative Breast Cancer
United States, Belgium, Canada, France, Georgia +11 more
Observational Study of Natural History of BAG3 Gene Mutation-Associated Dilated Cardiomyopathy in Chinese AdultsNot Yet Recruiting
NCT07646600N/AUpdated Jun 15, 2026
Sponsor: AstraZeneca
Dilated Cardiomyopathy
China
Multicenter, Observational, Descriptive Study of the Diagnosis, Course and Treatment of Patients With SLE in Routine Practice in Kazakhstan: a Registry Study With Retrospective and Prospective Components.Active Not Recruiting
NCT06899633N/AUpdated Jun 15, 2026
Sponsor: AstraZeneca
Description of SLE Activity in Patients in Routine Practice in the Republic of Kazakhstan · Description of the Course of SLE in Patients in the Republic of Kazakhstan · Description of Methods and Approaches to the Treatment of Patients With SLE in the Republic of Kazakhstan
Kazakhstan

Previous page Next page